Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
For primary objectives, we will determine the MTD and examine clinical responses and immune
cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507.
For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum
concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and
recovery of CD2 positive and total T-Cell populations.